Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
senicapoc
Description:
Senicapoc is a small-molecule inhibitor of the KCa3.1 potassium channel, investigated as a drug candidate in clinical and preclinical research.
Related topics:
Ion channel regulation and function (14%),
Hemoglobinopathies and Related Disorders (14%),
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (12%),
Respiratory Support and Mechanisms (8%)
Wikidata ID:
wiki/Q7450628
OpenAlex ID:
keywords/senicapoc
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
2008
·
Kenneth I. Ataga
, Wally R. Smith
, et al.
·
Blood
·
257
PDF
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso‐occlusive crises in patients with sickle cell disease: a phase III randomized, placebo‐controlled, double‐blind study of the gardos channel blocker senicapoc (ICA‐17043)
2011
·
Kenneth I. Ataga
, Marvin Reid
, et al.
·
British Journal of Haematology
·
237
Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease
2019
·
Lee‐Way Jin
, Jacopo Di Lucente
, et al.
·
Annals of Clinical and Translational Neurology
·
80
PDF
Sickle cell dehydration: Pathophysiology and therapeutic applications
2018
·
Carlo Brugnara
·
Clinical Hemorheology and Microcirculation
·
70
Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases
2020
·
Katy M. Roach
, Peter Bradding
·
British Journal of Pharmacology
·
68
Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDSs) for senicapoc
2020
·
Aristote B. Buya
, Bernard Ucakar
, et al.
·
International Journal of Pharmaceutics
·
65
Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia
2009
·
Kenneth I Ataga
, Jonathan Stocker
·
Expert Opinion on Investigational Drugs
·
62
The K+ Channel KCa3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis
2013
·
Katy Morgan Roach
, Stephen Mark Duffy
, et al.
·
PLoS ONE
·
61
PDF
Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea
2019
·
Tianying Duan
, Onur Cil
, et al.
·
JCI Insight
·
56
PDF
A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
2018
·
Katy M. Roach
, Amanda Sutcliffe
, et al.
·
Scientific Reports
·
55
PDF
KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
2017
·
Brandon M. Brown
, Brandon Pressley
, et al.
·
Current Neuropharmacology
·
54
PDF
Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore
2017
·
Hai M. Nguyen
, Vikrant Singh
, et al.
·
Molecular Pharmacology
·
49
PDF
Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
2021
·
KM Roach
, E Castells
, et al.
·
Frontiers in Pharmacology
·
45
Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel
2016
·
Raphael Rapetti-Mauss
, Olivier Soriani
, et al.
·
Haematologica
·
45
Inhibition of the KCa3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model
2017
·
Louise Organ
, Barbara Bacci
, et al.
·
American Journal of Respiratory Cell and Molecular Biology
·
39
PDF
The potassium channel KCa3.1 represents a valid pharmacological target for microgliosis-induced neuronal impairment in a mouse model of Parkinson’s disease
2019
·
Jia Lu
, Fangfang Dou
, et al.
·
Journal of Neuroinflammation
·
38
PDF
Drugs for preventing red blood cell dehydration in people with sickle cell disease
2016
·
Srikanth Nagalla
, Samir K Ballas
·
Cochrane Database of Systematic Reviews
·
38
KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology in a Sheep Model of Chronic Asthma
2013
·
Joanne Van Der Velden
, Grace Sum
, et al.
·
PLoS ONE
·
38
Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel‐like activity inhibited by senicapoc
2017
·
Alicia Rivera
, David H. Vandorpe
, et al.
·
American Journal of Hematology
·
34
Inhibition of the potassium channel K Ca 3.1 by senicapoc reverses tactile allodynia in rats with peripheral nerve injury
2016
·
Roland G.W. Staal
, Tanzilya Khayrullina
, et al.
·
European Journal of Pharmacology
·
34
KCa3.1—a microglial target ready for drug repurposing?
2016
·
Elena Dale
, Roland G. W. Staal
, et al.
·
Glia
·
33
KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)
2021
·
Felix Glaser
, Petra Hundehege
, et al.
·
Scientific Reports
·
29
PDF
Mechanistic ion channel interactions in red cells of patients with Gárdos channelopathy
2021
·
Julia Jansen
, Min Qiao
, et al.
·
Blood Advances
·
28
Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke
2017
·
Roland G. W. Staal
, Jonathan R. Weinstein
, et al.
·
Neurochemical Research
·
28
Targeting Kca3.1 Channels in Cancer
2021
·
Luca Matteo Todesca
, Sarah Maskri
, et al.
·
Cellular Physiology and Biochemistry
·
26
PDF
Show more works
View as search
Works count:
126
Citation count:
2,063
Year
Topic
Type